Zydus Cadila posts consolidated revenues of Rs. 3785 crore in Q2
NEW DELHI: For the second quarter ended September 30, 2021, Zydus Cadila posted consolidated revenue of Rs. 3785 crore, up 3% on a y-o-y basis. Earnings before Interest, Depreciation and Tax (EBIDTA) for the quarter was Rs. 861 crore, up by 6% y-o-y. The EBIDTA margin for the quarter was 22.7%, an improvement of 50 […]
Zydus Cadila gets DCGI approval to initiate Phase-3 clinical trials for COVID-19 vaccine
NEW DELHI: Zydus Cadila, an innovation driven global pharmaceutical company focused on discovering and developing NCEs, Novel Biologicals, Biosimilars and Vaccines, announced that it will be starting Phase III clinical trials of it plasmid DNA vaccine to prevent COVID-19, ZyCoV-D after having received permissions from the DCGI. The company will now be initiating Phase III […]
Zydus Cadila receives tentative approval from USFDA for Dapagliflozin Tablets
NEW DELHI: Zydus Cadila said that it has received tentative approval from the USFDA to market Dapagliflozin Tablets, 5 mg and 10 mg (US RLD: Farxiga Tablets). Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus and […]